AR054444A2 - Mezcla en forma solida de rapamicina o un derivado se rapamicina y un antioxidante - Google Patents

Mezcla en forma solida de rapamicina o un derivado se rapamicina y un antioxidante

Info

Publication number
AR054444A2
AR054444A2 ARP060101807A ARP060101807A AR054444A2 AR 054444 A2 AR054444 A2 AR 054444A2 AR P060101807 A ARP060101807 A AR P060101807A AR P060101807 A ARP060101807 A AR P060101807A AR 054444 A2 AR054444 A2 AR 054444A2
Authority
AR
Argentina
Prior art keywords
rapamycin
antioxidant
derivative
solid form
weight
Prior art date
Application number
ARP060101807A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26314797&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR054444(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR054444A2 publication Critical patent/AR054444A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Una mezcla en forma solida comprende una rapamicina o un derivado de rapamicina que tiene propiedades inmunosupresoras y un antioxidante, donde el antioxidante está presente en una cantidad de desde más del 0 al 1% en base al peso de la rapamicina o del derivado de rapamicina.
ARP060101807A 1998-12-07 2006-05-04 Mezcla en forma solida de rapamicina o un derivado se rapamicina y un antioxidante AR054444A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9826882.4A GB9826882D0 (en) 1998-12-07 1998-12-07 Organic compounds
GBGB9904934.8A GB9904934D0 (en) 1998-12-07 1999-03-04 Organic compounds

Publications (1)

Publication Number Publication Date
AR054444A2 true AR054444A2 (es) 2007-06-27

Family

ID=26314797

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP990106171A AR026102A1 (es) 1998-12-07 1999-12-03 Un proceso para estabilizar un mocrolido de polietileno, una mezcla de forma solida, una composicion farmaceutica, un derivado de rapamicina y un procesopara su purificacion
ARP050100744A AR048073A2 (es) 1998-12-07 2005-02-28 40-o-(2-hidroxi-etil)-rapamicina, proceso para su produccion y composicion farmaceutica que la contiene
ARP060101807A AR054444A2 (es) 1998-12-07 2006-05-04 Mezcla en forma solida de rapamicina o un derivado se rapamicina y un antioxidante

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ARP990106171A AR026102A1 (es) 1998-12-07 1999-12-03 Un proceso para estabilizar un mocrolido de polietileno, una mezcla de forma solida, una composicion farmaceutica, un derivado de rapamicina y un procesopara su purificacion
ARP050100744A AR048073A2 (es) 1998-12-07 2005-02-28 40-o-(2-hidroxi-etil)-rapamicina, proceso para su produccion y composicion farmaceutica que la contiene

Country Status (38)

Country Link
US (5) US6605613B2 (es)
EP (4) EP2279751A3 (es)
JP (3) JP3805625B2 (es)
KR (2) KR20060096477A (es)
CN (2) CN1876657B (es)
AR (3) AR026102A1 (es)
AT (1) ATE365051T1 (es)
AU (1) AU759219B2 (es)
BE (1) BE1012869A3 (es)
BR (1) BR9915986A (es)
CA (3) CA2351580C (es)
CO (1) CO4980847A1 (es)
CY (1) CY1106870T1 (es)
CZ (2) CZ302210B6 (es)
DE (1) DE69936352T3 (es)
DK (1) DK1137439T4 (es)
ES (1) ES2288033T5 (es)
FR (1) FR2786771B1 (es)
GB (2) GB9826882D0 (es)
HK (1) HK1038889B (es)
HU (2) HU228939B1 (es)
ID (1) ID29250A (es)
IL (1) IL143092A0 (es)
IT (1) IT1319701B1 (es)
MY (2) MY127579A (es)
NO (2) NO332698B1 (es)
NZ (2) NZ511936A (es)
PE (1) PE20001333A1 (es)
PL (2) PL208854B1 (es)
PT (1) PT1137439E (es)
RU (1) RU2243769C2 (es)
SG (1) SG151072A1 (es)
SI (1) SI1137439T2 (es)
SK (2) SK286688B6 (es)
TR (2) TR200201428T2 (es)
TW (2) TWI270550B (es)
WO (1) WO2000033878A2 (es)
ZA (1) ZA200104360B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US7452692B2 (en) 2002-02-13 2008-11-18 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Method for extracting a macrolide from biomatter
ZA200406350B (en) 2002-02-13 2006-11-29 Teva Gyogyszergyar Reszveny Tarsasag Method for extracting a macrolide from biomatter
DK1553940T3 (da) 2002-07-30 2008-06-02 Wyeth Corp Patenterale formuleringer indeholdende en rapamycin-hydroxyester
TW200504079A (en) 2003-03-31 2005-02-01 Biogal Gyogyszergyar Crystallization and purification of macrolides
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
US7220357B2 (en) 2003-07-24 2007-05-22 Teva Gyógyszergyár Zártkörúen Múkó´dó´Résvénytársaság Method of purifying macrolides
US9114198B2 (en) * 2003-11-19 2015-08-25 Advanced Cardiovascular Systems, Inc. Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
CN1889994A (zh) * 2003-12-10 2007-01-03 艾克若克斯Dds有限公司 伴随透皮或局部药物输送的不希望的效果的治疗方法
US8551512B2 (en) * 2004-03-22 2013-10-08 Advanced Cardiovascular Systems, Inc. Polyethylene glycol/poly(butylene terephthalate) copolymer coated devices including EVEROLIMUS
MX2007003731A (es) * 2004-09-29 2007-08-14 Johnson & Johnson Formas de dosis farmaceuticas de compuestos similares a rapamicina amorfos estables.
US8637070B2 (en) 2005-02-09 2014-01-28 Santen Pharmaceutical Co., Ltd. Rapamycin formulations and methods of their use
JP2009518648A (ja) * 2005-12-07 2009-05-07 ワイス 結晶性ラパマイシンを調製するための方法およびを示差走査熱量測定使用してラパマイシン化合物の結晶化度を測定するための方法
US7700614B2 (en) * 2005-12-14 2010-04-20 Abbott Laboratories One pot synthesis of tetrazole derivatives of rapamycin
CN101340901A (zh) * 2005-12-20 2009-01-07 惠氏公司 通过控制药物物质杂质控制cci-779剂型稳定性
EP2001438A2 (en) * 2006-02-09 2008-12-17 Macusight, Inc. Stable formulations, and methods of their preparation and use
ES2563288T3 (es) 2006-03-23 2016-03-14 Santen Pharmaceutical Co., Ltd Rapamicina en dosis bajas para el tratamiento de enfermedades relacionadas con la permeabilidad vascular
AU2011260016B2 (en) 2010-06-02 2013-08-22 Fresenius Kabi Oncology Ltd. Stable pharmaceutical compositions of Rapamycin esters
JP2013529224A (ja) * 2010-06-07 2013-07-18 テリック，インコーポレイテッド 結晶性エザチオスタット塩酸塩非溶媒和物
US9321782B2 (en) * 2010-08-04 2016-04-26 Meril Life Sciences Pvt. Ltd. Process for preparation of novel 42-O-(heteroalkoxyalkyl) rapamicin compounds with anti-proliferative properties
ES2753529T3 (es) 2010-11-19 2020-04-13 Biocon Ltd Procesos para la preparación de everolimús y productos intermedios del mismo
US8809562B2 (en) 2011-06-06 2014-08-19 Chevron Phillips Chemical Company Lp Use of metallocene compounds for cancer treatment
WO2013022201A1 (en) * 2011-08-11 2013-02-14 Dong-A Pharm. Co., Ltd. Process of preparing a stabilized and solubilized formulation of sirolimus derivatives
US9610385B2 (en) 2013-03-07 2017-04-04 Abbott Cardiovascular Systems Inc. Method of fabricating an implantable medical device comprising a rapamycin derivative
IN2013MU02532A (es) 2013-07-31 2015-06-26 Sahajanand Medical Technologies Pvt Ltd
CN104721158B (zh) * 2013-12-24 2018-01-30 正大天晴药业集团股份有限公司 一种稳定的依维莫司片剂
CN104892632B (zh) * 2015-06-03 2017-12-26 道中道（菏泽）制药有限公司 一种晶体形式的依维莫司及其制备方法
EP3329916A4 (en) 2015-07-28 2019-03-20 Nippon Kayaku Kabushiki Kaisha PHARMACEUTICAL COMPOSITION COMPRISING RAPAMYCIN OR A DERIVATIVE THEREOF, AND PROCESS FOR PRODUCING THE SAME
EP3342410A4 (en) * 2015-08-28 2019-04-24 Nippon Kayaku Kabushiki Kaisha PHARMACEUTICAL COMPOSITION WITH RAPAMYCIN OR DERIVATIVES THEREOF
US20190038605A1 (en) * 2015-09-18 2019-02-07 Nippon Kayaku Kabushiki Kaisha Pharmaceutical composition comprising rapamycin or derivative thereof
WO2017129772A1 (en) 2016-01-29 2017-08-03 Xellia Phamaceuticals Aps Stable pharmaceutical compositions of temsirolimus
EP3466424A1 (en) 2016-05-27 2019-04-10 Nippon Kayaku Kabushiki Kaisha Pharmaceutical composition comprizing rapamycin or derivative thereof
KR102051806B1 (ko) * 2018-01-12 2019-12-04 주식회사 종근당 에베로리무스를 포함하는 안정화된 약제학적 제제
EP4126882A1 (en) * 2020-03-27 2023-02-08 Boston Scientific Scimed Inc. Methods for crystallization of drugs
JP2023028473A (ja) * 2021-08-19 2023-03-03 日本マイクロバイオファーマ株式会社 エベロリムスの製造方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3996355A (en) 1975-01-02 1976-12-07 American Home Products Corporation Permanent suspension pharmaceutical dosage form
US4049128A (en) 1976-11-18 1977-09-20 Westinghouse Air Brake Company Control system for automatic railway car coupler
AU543727B2 (en) * 1980-06-02 1985-05-02 Ayerst Mckenna & Harrison Inc. Injectable composition of rapamycin
GB8803836D0 (en) 1988-02-18 1988-03-16 Glaxo Group Ltd Compositions
JPH01249651A (ja) † 1988-02-18 1989-10-04 E I Du Pont De Nemours & Co セラミツク／蒸留可能な結合剤組成物
KR0159766B1 (ko) * 1989-10-16 1998-12-01 후지사와 토모키치로 양모제 조성물
JPH04230389A (ja) * 1990-07-16 1992-08-19 American Home Prod Corp ラパマイシン誘導体
FI97472C (fi) 1991-05-07 1996-12-27 American Home Prod Menetelmä terapeuttisesti käyttökelpoisten rapamysiinijohdannaisten valmistamiseksi anti-inflammatorisina ja antifungaalisina aineina
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5302584A (en) * 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
EP0593227B1 (en) 1992-10-13 2006-03-22 Wyeth Carbamates of rapamycin
DK0833828T3 (da) 1995-06-09 2003-03-17 Novartis Ag Rapamycinderivater
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
CA2261666C (en) * 1996-07-30 2010-09-14 Novartis Ag Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-0-(2-hydroxiethyl)-rapamycin
US6362264B1 (en) * 1996-12-20 2002-03-26 Ck Witco Corporation Stabilizer for food contact and medical grade PVC
WO1998033482A1 (en) 1997-02-04 1998-08-06 Abbott Laboratories Pain reducing parenteral liposome formulation

Also Published As

Publication number Publication date
US7297703B2 (en) 2007-11-20
HUP0104489A3 (en) 2004-05-28
ZA200104360B (en) 2002-01-16
CA2351580C (en) 2012-03-20
CA2351580A1 (en) 2000-06-15
US20050107418A1 (en) 2005-05-19
NO332698B1 (no) 2012-12-10
PL208854B1 (pl) 2011-06-30
EP1743657A3 (en) 2007-03-28
JP5043308B2 (ja) 2012-10-10
NO334612B1 (no) 2014-04-22
GB9826882D0 (en) 1999-01-27
ES2288033T5 (es) 2012-04-10
EP1743657A2 (en) 2007-01-17
HK1038889A1 (en) 2002-04-04
IL143092A0 (en) 2002-04-21
US7741338B2 (en) 2010-06-22
AU1657300A (en) 2000-06-26
US6605613B2 (en) 2003-08-12
IT1319701B1 (it) 2003-10-27
FR2786771B1 (fr) 2002-12-27
US20020032213A1 (en) 2002-03-14
US7572804B2 (en) 2009-08-11
CN1876657A (zh) 2006-12-13
US20080161334A1 (en) 2008-07-03
HUP0104489A2 (hu) 2002-03-28
CN1374872A (zh) 2002-10-16
CO4980847A1 (es) 2000-11-27
US6852729B2 (en) 2005-02-08
DK1137439T4 (da) 2012-03-19
SI1137439T1 (sl) 2008-06-30
NZ527781A (en) 2004-11-26
JP2005200429A (ja) 2005-07-28
EP1137439B1 (en) 2007-06-20
AR048073A2 (es) 2006-03-29
US20030191148A1 (en) 2003-10-09
EP1137439A2 (en) 2001-10-04
NO20012424L (no) 2001-05-16
PL196627B1 (pl) 2008-01-31
NZ511936A (en) 2003-10-31
CZ303006B6 (cs) 2012-02-22
CA2651609A1 (en) 2000-06-15
MY120594A (en) 2005-11-30
HK1038889B (zh) 2008-01-25
HU228939B1 (en) 2013-07-29
SK287325B6 (sk) 2010-07-07
CA2732620C (en) 2013-08-06
AR026102A1 (es) 2003-01-29
ITMI992520A1 (it) 2001-06-02
TR200201428T2 (tr) 2002-12-23
ITMI992520A0 (it) 1999-12-02
TR200101416T2 (tr) 2002-01-21
CZ302210B6 (cs) 2010-12-22
ES2288033T3 (es) 2007-12-16
GB9904934D0 (en) 1999-04-28
JP2002531527A (ja) 2002-09-24
KR20060096477A (ko) 2006-09-11
CN1876657B (zh) 2013-01-09
MY127579A (en) 2006-12-29
WO2000033878A2 (en) 2000-06-15
HU230174B1 (hu) 2015-09-28
ATE365051T1 (de) 2007-07-15
BE1012869A3 (fr) 2001-04-03
PE20001333A1 (es) 2000-12-12
JP3805625B2 (ja) 2006-08-02
DE69936352D1 (de) 2007-08-02
CY1106870T1 (el) 2012-09-26
DK1137439T3 (da) 2007-09-10
DE69936352T3 (de) 2012-05-03
US20090270441A1 (en) 2009-10-29
DE69936352T2 (de) 2008-02-14
EP2279751A3 (en) 2011-02-16
NO20121113L (no) 2001-05-16
KR100695834B1 (ko) 2007-03-19
CZ20012001A3 (cs) 2001-09-12
FR2786771A1 (fr) 2000-06-09
EP2269651A3 (en) 2011-03-09
TWI248938B (en) 2006-02-11
JP2006111637A (ja) 2006-04-27
TWI270550B (en) 2007-01-11
BR9915986A (pt) 2001-09-04
AU759219B2 (en) 2003-04-10
SG151072A1 (en) 2009-06-29
NO20012424D0 (no) 2001-05-16
PT1137439E (pt) 2007-09-25
KR20010101128A (ko) 2001-11-14
EP2279751A2 (en) 2011-02-02
ID29250A (id) 2001-08-16
SK7662001A3 (en) 2001-12-03
WO2000033878A3 (en) 2000-11-02
EP2269651A2 (en) 2011-01-05
TW200540179A (en) 2005-12-16
SK286688B6 (sk) 2009-03-05
CN1261163C (zh) 2006-06-28
JP5165199B2 (ja) 2013-03-21
CA2732620A1 (en) 2000-06-15
PL348333A1 (en) 2002-05-20
EP1137439B2 (en) 2011-11-23
RU2243769C2 (ru) 2005-01-10
SI1137439T2 (sl) 2012-05-31

Similar Documents

Publication Publication Date Title
AR054444A2 (es) Mezcla en forma solida de rapamicina o un derivado se rapamicina y un antioxidante
SV2004001474A (es) Formas de dosificacion de liberacion inmediata que contienen dispersiones de farmaco solido ref. pc23278
BR0312116A (pt) Artigo
AR030724A1 (es) Un metodo para formar articulos termoendurecidos reforzados y los articulos termoendurecidos reforzados producidos por el mismo
DK0679154T3 (da) Ny krystallinsk form af en d-vitamininanalog
ES2080134T3 (es) Compuestos fotocromicos de tipo indolino-espiro-oxazina, su procedimiento de preparacion, composiciones y articulos fotocromicos que contienen dichos compuestos.
AR034737A1 (es) Conjunto de elementos de desgaste
MY122619A (en) Ethylene/a-olefin copolymer, method for producing the same, and use thereof
ES2148120T3 (es) Metodo para la preparacion de citalopram.
GT200100008A (es) Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
CY1105366T1 (el) Ανθελμινθικες συνθεσεις
UY27067A1 (es) Pirrolo (2.-a) dihidroisoquinolinas
CO5700769A2 (es) Composicion farmaceutica de liberacion prolongada
AR004786A1 (es) Un procedimiento para la preparación de una composicion asfaltica de grado denso con un volumen total de huecos no mayor que el 10% y uso de la misma para aplicaciones en caminos
ES2166504T3 (es) Compuestos de nitrogeno acilados que pueden ser utilizados como aditivos para un aceite lubricante y en composiciones combustibles.
ATE247617T1 (de) Entzendungshemmende antibakterielle benzylphenolverbindungen
ECSP034531A (es) Derivados sustituidos de c-ciclohexilmetilamina
AR023690A1 (es) Combinaciones de espesadores asociativos y composiciones acuosas para revestimientos protectores, uso de las mismas y producto revestido con dichacomposicion
UY27203A1 (es) Bencimidazoles útiles en el tratamiento de la disfunción sexual
ES2062294T5 (es) Uso de un aditivo como detergente, dispersante y antioxidante para combustibles y aceites lubricantes.
BR9608362A (pt) Anel de vedaçao
ES2082424T3 (es) 1-aminonaftalenos sustituidos y composiciones estabilizadas.
EA200400211A1 (ru) Лиофилизованная композиция 2-метилтиенобензодиазепина
ATE414123T1 (de) Polyamide-zusammensetzungen enthaltend antioxidantien
BR0011261A (pt) Composição oral compreendendo perlita, e, uso de perlita

Legal Events

Date Code Title Description
FG Grant, registration